Journal of Pancreatology (Jun 2024)
Consensus on the clinical diagnosis and treatment of grade 3 pancreatic neuroendocrine tumors
- Jie Chen,
- Wenming Wu,
- Chunmei Bai,
- Yihebali Chi,
- Li Huo,
- Liming Jiang,
- Yuan Ji,
- Jie Luo,
- Jie Li,
- Jingnan Li,
- Wenhui Lou,
- Chenghao Shao,
- Lin Shen,
- Feng Wang,
- Yu Wang,
- Ling Xue,
- Jin Xu,
- Chunhui Yuan,
- Xianjun Yu,
- Xiaoyu Yin,
- Hong Zhao,
- Xiongzeng Zhu,
- Yupei Zhao
Affiliations
- Jie Chen
- a Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai 200032, China
- Wenming Wu
- b Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China
- Chunmei Bai
- c Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China
- Yihebali Chi
- d Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Li Huo
- e Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
- Liming Jiang
- f Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
- Yuan Ji
- g Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
- Jie Luo
- h Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China
- Jie Li
- i Department of Gastroenterological Oncology, Beijing Cancer Hospital, Peking University Cancer Hospital & Institute, Beijing 100142, China
- Jingnan Li
- j Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
- Wenhui Lou
- k Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
- Chenghao Shao
- l Department of Pancreatic-Biliary Surgery, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China
- Lin Shen
- m Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China
- Feng Wang
- n Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China
- Yu Wang
- o Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
- Ling Xue
- p Department of Pathology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China
- Jin Xu
- q Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Pancreatic Cancer Institute Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai 200032, China
- Chunhui Yuan
- r Department of General Surgery, Peking University Third Hospital, Beijing 100191, China
- Xianjun Yu
- q Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Pancreatic Cancer Institute Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai 200032, China
- Xiaoyu Yin
- s Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
- Hong Zhao
- t Department of Hepatobiliary Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China
- Xiongzeng Zhu
- u Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
- Yupei Zhao
- b Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China
- DOI
- https://doi.org/10.1097/JP9.0000000000000183
- Journal volume & issue
-
Vol. 7,
no. 2
pp. 97 – 105
Abstract
The World Health Organization (WHO) 2017 classifications for neuroendocrine neoplasms (NENs) subdivided grade 3 pancreatic neuroendocrine neoplasms (pNENs) into G3 well-differentiated pancreatic neuroendocrine tumors (G3 pNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (pNECs), according to the mitotic count, Ki-67 index, and cell differentiation. As a new category, G3 pNETs remain a challenging group of tumors to manage by lacking large randomized trials and consensus to support its clinical practice. Therefore, the Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association gathered experts in this field to formulate this consensus for the diagnosis and treatment of G3 pNETs.
